To investigate the impact of MSI2 in CAFs on NSCLC progression, we genetically depleted MSI2 in CAFs (gMSI2 CAFs) using a lentivirus containing gRNA sequence against MSI2 using CRISPR-Cas9 technology (Fig. 2A). The gene discussed is MSI2; the disease is non-small cell lung carcinoma.